IM Cannabis (NASDAQ: IMCC) is one of 43 public companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare IM Cannabis to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.
Insider & Institutional Ownership
13.7% of IM Cannabis shares are owned by institutional investors. Comparatively, 17.9% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 30.9% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares IM Cannabis and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IM Cannabis Competitors||-196.99%||-84.80%||-18.10%|
Valuation and Earnings
This table compares IM Cannabis and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|IM Cannabis||$11.86 million||-$21.42 million||-5.98|
|IM Cannabis Competitors||$220.78 million||-$89.53 million||-16.22|
IM Cannabis’ peers have higher revenue, but lower earnings than IM Cannabis. IM Cannabis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a summary of current recommendations for IM Cannabis and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IM Cannabis Competitors||221||604||580||12||2.27|
IM Cannabis presently has a consensus price target of $8.75, suggesting a potential upside of 165.96%. As a group, “Medicinals & botanicals” companies have a potential upside of 43.87%. Given IM Cannabis’ stronger consensus rating and higher possible upside, research analysts clearly believe IM Cannabis is more favorable than its peers.
IM Cannabis beats its peers on 8 of the 12 factors compared.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel, Germany, and Canada. It offers strains under the Roma, Dairy Queen, London, Tel Aviv, Paris, and Pandora Box brands; and CBD oil products under the IMC brand. The company also offers its intellectual property related services to the medical cannabis industry. IM Cannabis Corp. is headquartered in Tel Aviv-Yafo, Israel.
Receive News & Ratings for IM Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IM Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.